FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Quinoline topics
Isoquinolin
Praziquantel
Carbon Atoms
Crystallin
Quinoline Derivatives
Pharmaceutically Acceptable Salt
Alkyl Group
Cycloalkyl
Pharmaceutically Acceptable Salts
Immunodeficiency
Retrovirus
Viral Infection
Human Immunodeficiency Virus
Angiogenesis
Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Quinoline patents



      
           
This page is updated frequently with new Quinoline-related patents. Subscribe to the Quinoline RSS feed to automatically get the update: related Quinoline RSS feeds.

Subscribe to updates on this page: Quinoline RSS RSS

Date/App# patent app List of recent Quinoline-related patents
04/17/14
20140107153
 Therapeutic quinoline and naphthalene derivatives patent thumbnailnew patent Therapeutic quinoline and naphthalene derivatives
Therapeutic methods, compositions, and medicaments related thereto are also disclosed.. .
04/17/14
20140107127
 Pyrazinoisoquinoline compounds patent thumbnailnew patent Pyrazinoisoquinoline compounds
This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
04/17/14
20140103305
 5-substituted 2-phenylquinoline complexes materials for light emitting diode patent thumbnailnew patent 5-substituted 2-phenylquinoline complexes materials for light emitting diode
Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a bulky alkyl at the 5-position.
04/10/14
20140100234
 Quinoline derivatives as pi3 kinase inhibitors patent thumbnailQuinoline derivatives as pi3 kinase inhibitors
Invented is a method of inhibiting the activity/function of pi3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives..
03/27/14
20140088130
 Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof patent thumbnailHexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof
The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (i) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor.
03/27/14
20140088094
 N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease patent thumbnailN-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of rorgamma activity and the treatment of disease
The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting rorγ activity, reducing the amount of il-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.. .
03/27/14
20140088093
 Tricyclic tetrahydroquinoline antibacterial agents patent thumbnailTricyclic tetrahydroquinoline antibacterial agents
Described herein are antibacterial compounds, methods for making the compounds, pharmaceutical compositions containing the compounds and methods of treating bacterial infections utilizing the compounds and pharmaceutical composition.. .
03/20/14
20140080867
 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators patent thumbnailSubstituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
The invention relates to substituted 2-oxy-quinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.. .
03/20/14
20140080865
 Salts and solvates of a tetrahydroisoquinoline derivative patent thumbnailSalts and solvates of a tetrahydroisoquinoline derivative
(s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described..
03/20/14
20140080816
 Tricyclic quinoline and quinoxaline derivatives patent thumbnailTricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/20/14
20140080814
Tricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/20/14
20140080813
Tricyclic quinoline and quinoxaline derivatives
The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-ht2c receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-ht2c receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-ht2c receptor.. .
03/06/14
20140066470
Novel formulations of water-insoluble chemical compounds and methods of using a formulation of compound fl118 for cancer therapy
Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy.
03/06/14
20140066469
Treatment of diseases associated with inflammation
Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e.g. Hydroxychloroquine, and a statin, e.g.
03/06/14
20140066459
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
02/27/14
20140058109
Crystal form of quinoline compound and process for its production
The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form a, thereby to obtain a drug substance excellent in stability.. .
02/20/14
20140051723
Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
The subject invention provides deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.. .
02/20/14
20140050696
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention.
02/13/14
20140045834
7-(3,5-dimethyl-4-isoxazolyl)-8-(methyloxy)-1h-imidazo[4,5-c]quinoline derivatives
Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.. .
02/13/14
20140041133
Dye composition using a 2-hydroxynaphthalene, (acylamino)phenol or quinoline coupler in a fatty-substance-rich medium, dyeing process and device therefor
The present invention relates to a cosmetic composition for dyeing keratin fibres, in particular human keratin fibres such as the hair, comprising: a) one or more fatty substances; b) one or more surfactants; c) one or more oxidation bases; d) one or more couplers based on 2-hydroxynaphthalene derivatives or particular phenol derivatives, acylaminophenol derivatives or quinoline derivatives; f) one or more basifying agents; e) optionally one or more chemical oxidizing agents; and the fatty substance content representing in total at least 25% by weight relative to the total weight of the formulation. The present invention also relates to a process using this composition, and to a multi-compartment device that is suitable for performing the said process..
02/06/14
20140039006
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline derivatives, pharmaceutical compositions containing such compounds and to their use in therapy.. .
01/30/14
20140031544
Aryl-and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline
Wherein the variables r1, r2, r3, r4, and m are defined as in claim 1, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (hsd) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia..
01/30/14
20140031391
Novel 5-aminotetrahydroquinoline-2-carboxylic acids and their use
The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.. .
01/30/14
20140031336
Tetrahydroquinoline derivatives useful as bromodomain inhibitors
Tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and their use in therapy.. .
01/30/14
20140031276
Compounds and methods for preventing or treating a viral infection
A compound is provided which has a structure i: a-b-c and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which a is a quinoline or quinoline-like group, b is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and c is an o-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be q-vd-oph (n-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxy)methyl ketone), optionally in an o-methylated form.
01/23/14
20140024678
Stable laquinimod preparations
The subject invention provides a pharmaceutical composition comprising n-ethyl-n-phenyl-1,2,-dihydro-4-hydroxy-5- chloro-1-methyl-2-oxoquinoline-3-carboxamide or the salt thereof; a pharmaceutically acceptable carrier; and not more than 0.5% w/w relative to n-ethyl-n-phenyl-1,2,-dihydro-4 -hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide of 2-chloro-6-(1-ethyl-n-methyl-2-oxoindoline-3-carboxamido) benzoic acid, 1h,3h-spiro[5-chloro-1-methylquinoline-2,4 -dione-3,3′-[1]ethylindolin-[2]-one], or 5-chloro-n-ethyl-3-hydroxy-1-methyl-2,4-dioxo-n-phenyl-1,2,3,4 -tetrahydro-quinoline-3-carboxamide.. .
01/23/14
20140024676
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
01/23/14
20140024675
Crystalline forms of a prolyl hydroxylase inhibitor
The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
01/23/14
20140023666
Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.. .
01/16/14
20140018388
Quinoline derivatives and their use as tyrosine kinase inhibitors
6-(methylcarbamoyl)-4-[(4-methylphenyl)amino]quinoline-3-carboxylic acid, and pharmaceutically acceptable salts thereof, is provided. The compound can be used to treat cancer, diabetic retinopathy, age-related macular degeneration, inflammation, stroke, ischemic myocardium, atherosclerosis, macular edema and psoriasis..
01/16/14
20140018360
Azaindenoisoquinoline topoisomerase i inhibitors
The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase i, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.. .
01/09/14
20140011777
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
Imidazo-quinoline, -pyridine, and -naphthyridine ring systems (particularly quinolines, tetrahydroquinolines, pyridines, [1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at the 1-position with a cyclic substituent, pharmaceutical compositions containing the compounds, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.. .
01/02/14
20140005401
Process for preparing quinoline-3-carboxamide derivatives
Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of quinoline-3-carboxamide derivatives such as laquinimod, or a pharmaceutically acceptable salt thereof, in high yield and purity.. .
12/26/13
20130345462
Process for production of 4-oxoquinoline compound
Wherein r is a fluorine atom or a methoxy group, r1 is a c1-c4 alkyl group, r2 is a hydroxyl-protecting group, and x2 is a halogen atom, a production method thereof, and a production method of an anti-hiv agent using the synthetic intermediate.. .
12/26/13
20130345258
Amino-quinolines as kinase inhibitors
Wherein r1, r2, r3 and z are as defined herein, and methods of making and using the same.. .
12/26/13
20130345256
N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of n-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing n-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same.. .
12/26/13
20130345252
Synthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1)- topoisomerase i (top1) inhibitors
The invention described herein pertains to the synthesis and use of certain n-substituted indenoisoquinoline compounds which inhibit the activity tyrosyl-dna phosphodiesterase i (tdp1) or topoisomerase i (top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel n-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel n-substituted indenoisoquinoline compounds..
12/19/13
20130338366
Process for the preparation of pyrido [2,1-a] isoquinoline derivatives comprising optical resolution of an enamine
Wherein rco2− is the conjugate base of the resolving agent.. .
12/19/13
20130337511
Method for producing pyrroloquinoline quinone using a bacterium of the genus methylobacterium or hyphomicrobium
The present invention provides a method for producing pqq using a bacterium belonging to the genera methylobacterium or hyphomicrobium, which has been modified to enhance the expression of pqq gene cluster and/or gene(s) encoding a precursor for pqq biosynthesis.. .
12/12/13
20130331359
Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compounds and application
Phosphorus-containing group-substituted quinolines of formula (i) are provided in the present invention. The preparation process and application of the compound, and formulation comprising phosphorus-containing group-substituted quinolines are also disclosed.
12/12/13
20130330284
Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
8-hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and/or selective mao-ab inhibitory activities.. .
11/28/13
20130317187
Long chain-branched ethylene-alpha olefin copolymer
The present invention relates to an ethylene-alpha olefin copolymer comprising long chain branches (lcb), while having a narrow molecular weight distribution. The ethylene-alpha olefin copolymer can be prepared by a continuous solution polymerization process using an activated catalyst composition containing a group 4 transition metal compound having a monocyclopentadienyl ligand, to which a quinoline amino group is introduced..
11/28/13
20130317186
Long chain-branched ethylene-alpha olefin copolymer
The present invention relates to an ethylene-alpha olefin copolymer comprising long chain branches (lcb), while having a narrow molecular weight distribution. The ethylene-alpha olefin copolymer can be prepared by a continuous solution polymerization process using an activated catalyst composition containing a group 4 transition metal compound having a monocyclopentadienyl ligand, to which a quinoline amino group is introduced..
11/28/13
20130317060
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
The present invention relates to solid state forms of n—[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (compound 1), pharmaceutical compositions thereof and methods therewith.. .
11/28/13
20130317052
Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal mobility disorders..
11/28/13
20130317010
Tetrahydroisoquinoline derivative
To provide an excellent agent for preventing or treating dementia and schizophrenia based on serotonin 5-ht5a receptor regulating action, it was found that a tetrahydroisoquinoline derivative characterized by a structure in which an acylguanidino group binds to a n atom of a tetrahydroisoquinoline ring or the like, and a cyclic group binds to an unsaturated ring has a potent 5-ht5a receptor regulating action and an excellent pharmacological action based on the regulating action and also discovered that the tetrahydroisoquinoline derivative is useful as an agent for treating or preventing dementia, schizophrenia, and the like, whereby the present invention has been completed.. .
11/21/13
20130310595
Method for producing 4-oxoquinoline compound
Wherein r is a fluorine atom or a methoxy group, and r400 is a hydrogen atom or a c1-c4 alkyl group, or a salt thereof, and a production method thereof, and a production method of an anti-hiv agent using the synthetic intermediate.. .
11/21/13
20130310557
Amorphous besifloxacin solid
Amorphous solid-state form of (r)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1h-azepin-1-yl)-1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an x-ray powder diffraction (“xrpd”) spectrum that comprises peaks at 2θ angles of 6.9-7.1, 9.4, 10.6-10.7, and 13.4-13.7°±0.2°, and a diffuse halo pattern at 11-30°; and (b) a dsc (differential scanning calorimetry) melting peak at about 267-272° c. The amorphous solid is prepared by rapid precipitation from a saturated or supersaturated solution of besifloxacin free base in a solvent comprising at least benzyl alcohol..
11/21/13
20130310374
Substituted imidazoquinoline derivatives
The present invention relates to substituted imidazo[4,5-c]quinoline derivatives of formula (i), wherein r1, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions comprising compounds of the present invention and their use in the treatment of diseases or disorders mediated by one or more kinases, particularly proliferative diseases or disorders such as cancer. These compounds can also be used in the treatment of inflammation and angiogenesis related disorders..
11/21/13
20130310370
Drug therapy for preventing or treating glaucoma
There is provided a drug therapy for prevention of glaucoma or prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. Disclosed is a combination of (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof, and a prostaglandin for prevention or treatment of glaucoma..
11/21/13
20130310348
Quinoline derivatives and uses thereof
This disclosure provides a new class of compounds referred to as “reversed chloroquines” (rcqs), which are highly effective against cqr and cqs malaria parasites. Rcqs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a cqr reversal moiety.
11/14/13
20130303560
Combination
The present invention relates to a method of treating breast cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a breast cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and (s)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1h-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14-(4h,12h)-dione, or a pharmaceutically acceptable salt thereof, to a human in need thereof..
11/14/13
20130303522
Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1
The compounds of formula (i) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, alzheimer's disease or neurodegeneration.. .
11/14/13
20130299795
Materials for organic light emitting diode
Compounds are provided that comprise a ligand having a 5-substituted 2-phenylquinoline. In particular, the 2-phenylquinoline may be substituted with a cycloalkyl containing group at the 5-position.
11/07/13
20130296571
Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders..
11/07/13
20130296365
Quinoline derivative-containing pharmaceutical composition
Wherein, r1 is a hydrogen atom, a c1-6 alkyl group or a c3-8 cycloalkyl group; and r2 is a hydrogen atom or a methoxy group.. .
11/07/13
20130296363
Quinoline and isoquinoline derivatives for use as jak modulators
Provided herein are compounds for treatment of jak kinase mediated diseases, including jak2 kinase-, jak3 kinase- or tyk2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions..
11/07/13
20130296360
Benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (vmat2), pharmaceutical compositions thereof, and methods of use thereof.. .
11/07/13
20130296352
Pyrazoloquinoline derivatives
Wherein r1 is a hydrogen atom; r2 is an aromatic ring group, etc.; r3 is a hydrogen atom, etc; r4 is a hydrogen atom; r5 is an oxepanyl group, etc.; r6 is a hydrogen atom.. .
11/07/13
20130296338
Quinoline and quinoxaline derivatives as kinase inhibitors
A series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of p13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.. .
11/07/13
20130296300
Quinolines and aza-quinolines as crth2 receptor modulators
The invention provides certain quinolines and aza-quinolines of the formula (i), and their pharmaceutically acceptable salts, wherein e, j1, ja, jb, r2, r3, r22, ra, rb, rc, rd, x, y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
11/07/13
20130296215
Water-rich stripping and cleaning formulation and method for using same
The present invention relates to water-rich formulations and the method using same, to remove bulk photoresists, post-etched and post-ashed residues, residues from al back-end-of-the-line interconnect structures, as well as contaminations. The formulation comprises: hydroxylamine; corrosion inhibitor containing a mixture of alkyl dihydroxybenzene and hydroxyquinoline; an alkanolamine, a water-soluble solvent or the combination of the two; and at least 50% by weight of water..


Popular terms: [SEARCH]

Quinoline topics: Isoquinolin, Praziquantel, Carbon Atoms, Crystallin, Quinoline Derivatives, Pharmaceutically Acceptable Salt, Alkyl Group, Cycloalkyl, Pharmaceutically Acceptable Salts, Immunodeficiency, Retrovirus, Viral Infection, Human Immunodeficiency Virus, Angiogenesis, Sulfonamide

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Quinoline for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Quinoline with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.9654

3614

6 - 0 - 80